Abstract
In addition to protein kinase A (PKA), cAMP regulates the activity of cAMP-gated channels and Rap1-specific guanine nucleotide exchange factors. We tested the hypothesis that the targets of cAMP might also include regulators of the Ras protooncogene. In rat thyroid cells, thyrotropin (TSH) stimulates proliferation through a cAMP-mediated pathway that requires Ras activity. Interference with Ras impairs DNA synthesis stimulated by TSH as well as cAMP elevating agents and analogs, demonstrating that the requirement for Ras lies downstream of cAMP. Although cAMP stimulates proliferation, microinjection of the purified PKA catalytic subunit failed to do so, suggesting that factors in addition to PKA are required for cAMP-stimulated cell cycle progression. When added to thyroid cells expressing human Ha-Ras, TSH rapidly and markedly increased the proportion of GTP-bound Ras. Ras activity was increased within 1 min of TSH addition, maximal at 5–15 min, and declined to basal levels 30–60 min after hormone treatment. Cyclic AMP elevating agents elicited similar effects on Ras, indicating that TSH activates Ras through a cAMP-mediated pathway. Although cAMP-mediated, Ras activation by TSH and cAMP was independent of PKA activity. Moreover, cAMP-stimulated Ras activation was not impaired by tyrosine kinase inhibitors. These results indicate that cAMP activates targets in addition to PKA in thyroid cells, and that these targets may include regulators of Ras. The ability of cAMP elevating agents to activate Ras in addition to PKA may explain the inability of the PKA catalytic subunit to stimulate DNA synthesis in thyroid cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others
References
Al-Alawi N, Rose DW, Buckmaster C, Ahn N, Rapp U, Meinkoth J and Feramisco JR. . 1995 Mol. Cell. Biol. 15: 1162–1168.
Bos JL. . 1997 Biochim. Biophys. Acta. 1333: M19–M31.
Bos JL. . 1998 EMBO J. 17: 6776–6782.
Cass LA and Meinkoth JL. . 1998 Endocrinol. 139: 1991–1998.
Cass LA, Summers SA, Prendergast GV, Backer JM, Birnbaum MJ and Meinkoth JL. . 1999 Mol. Cell. Biol. 19: 5882–5891.
Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioko T and Hidaka H. . 1990 J. Biol. Chem. 265: 5267–5272.
Collins LR, Minden A, Karin M and Brown JH. . 1996 J. Biol. Chem. 271: 17349–17353.
Creedon DJ, Johnson EM, and Lawrence JC. . 1996 J. Biol. Chem. 271: 20713–20718.
Crespo P, Xu N, Simonds WF and Gutkind JS. . 1994 Nature 369: 418–420.
Daaka Y, Luttrell LM and Lefkowitz RJ. . 1997 Nature 390: 88–91.
DeRooij J and Bos JL. . 1997 Oncogene 14: 623–625.
DeRooij J, Zwartkruis FJT, Verheijen MHG, Cool RH, Nijman SMB, Wittinghofer A and Bos JL. . 1998 Nature 396: 474–477.
Downward J. . 1997 Adv. Sec. Messenger Phosphopro. Res. 31: 1–10.
Dremier S, Pohl V, Poteet-Smith C, Roger P, Corbin J, Doskeland SO, Dumont JE and Maenhaut C. . 1997 Mol. Cell. Biol. 17: 6717–6726.
Ebinue JO, Bottorff DA, Chan EYW, Stang SL, Dunn RJ and Stone JC. . 1998 Science 280: 1082–1086.
Fagin JA. . 1994 Annu. Rev. Med. 45: 45–52.
Fantozzi DA, Harootunian AT, Wen W, Taylor SS, Feramisco JR, Tsien RY and Meinkoth JL. . 1994 J. Biol. Chem. 269: 2676–2686.
Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME and Feig LA. . 1995 Nature 376: 524–527.
Fusco A, Berlinghieri MT, Fiore PPD, Portella G, Grieco M and Vecchio G. . 1987 Mol. Cel. Biol. 7: 3365–3370.
Hall A. . 1998 Science 279: 509–514.
Hofer F, Fields S, Schneider C and Martin GS. . 1994 Proc. Natl. Acad. Sci. USA 91: 11089–11093.
Iyengar R. . 1996 Science 271: 461–463.
Jiang Y, Ma W, Wan Y, Kozasa T, Hattori S and Huang X-Y. . 1998 Nature 395: 808–813.
Jordan JD, Carey KD, Stork PJS and Iyengar R. . 1999 J. Biol. Chem. 274: 21507–21510.
Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE and Graybiel AM. . 1998 Science 282: 2275–2279.
Kolch W, Philipp A, Mischak H, Dutil EM, Mullen TM, Feramisco JR, Meinkoth JL and Rose DW. . 1996 Oncogene 6: 1304–1314.
Kupperman E, Wen W and Meinkoth JL. . 1993 Mol. Cell. Biol. 13: 4477–4484.
Kupperman E, Wofford D, Wen W and Meinkoth JL. . 1996 Endocrinol. 137: 96–104.
Lemoine NR, Staddon S, Bond J, Wyllie FS, Shaw JJ and Wynford-Thomas D. . 1990 Oncogene 5: 1833–1837.
Luttrell LM, Biesen Tv, Hawes BE, Koch WJ, Krueger KM, Touhara K and Lefkowitz RJ. . 1997 Adv. Sec. Mess. Phosphopro. Res. 31: 263–277.
Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feightinger H, Duh Q-Y, Clark OH, Kawasaki E, Bourne HR and McCormick F. . 1990 Science 249: 655–659.
Meinkoth JL, Goldsmith PK, Spiegel AM, Feramisco JR and Burrow GN. . 1992 J. Biol. Chem. 267: 13239–13245.
Miller MJ, Prigent S, Kupperman E, Rioux L, Park S-H, Feramisco JR, White MA, Rutkowski JL and Meinkoth JL. . 1997 J. Biol. Chem. 272: 5600–5605.
Miller MJ, Rioux L, Prendergast GV, Cannon S, White MA and Meinkoth JL. . 1998 Mol. Cell. Biol. 18: 3718–3726.
Mochizuki N, Ohba Y, Kiyokawa E, Kurata T, Murakami T, Ozaki T, Kitabatake A, Nagashima K and Matsuda M. . 1999 Nature 400: 891–894.
Muca C and Vallar L. . 1994 Oncogene 9: 3647–3653.
Ohno M, Zannini M, Levy O, Carrasco N and DiLauro R. . 1999 Mol. Cell. Biol. 19: 2051–2060.
Parma J, Duprez L, Sande JV, Cochaux P, Gervy C, Mockel J, Dumont J and Vassart G. . 1993 Nature 365: 649–651.
Rothermel JD and Botelho LHP. . 1988 Biochem. J. 251: 757–762.
Rydel RE and Greene LA. . 1988 Proc. Natl. Acad. Sci. USA 85: 1257–1261.
Schubert D, LaCorbiere M, Whitlock C and Stallcup W. . 1978 Nature 273: 718–723.
Seidel MG, Klinger M, Freissmuth M and Holler C. . 1999 J. Biol. Chem. 274: 25833–25841.
Suarez HG, Villard JAd, Cailou B, Schlumberger M, Parmentier C and Monier R. . 1991 Oncogene 6: 677–679.
Wynford-Thomas D. . 1997 Horm. Res. 47: 145–157.
Zufall F, Shepherd GM and Barnstable CJ. . 1997 Curr. Opin. Neurobiol. 7: 404–412.
Acknowledgements
Since submission of this manuscript, a cAMP regulated Ras GEF was described (N. Pham, 2000, Curr Biol: 10, 555). We are grateful for helpful suggestions from Dr Margaret Chou regarding the Ras activation assay and from Lisa Cass regarding preparation of this manuscript. This work was supported by PHS grants DK45696 and DK02494 awarded to JL Meinkoth.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsygankova, O., Kupperman, E., Wen, W. et al. Cyclic AMP activates Ras. Oncogene 19, 3609–3615 (2000). https://doi.org/10.1038/sj.onc.1203680
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1203680
Keywords
This article is cited by
-
G Protein regulation of MAPK networks
Oncogene (2007)
-
HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway
Journal of Molecular Medicine (2006)
-
G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Gαi regulated pathway
Oncogene (2004)
-
Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells
Oncogene (2001)


